About Altor Bioscience
Altor Bioscience is a company based in United States founded in 2002 by Hing Wong was acquired by NantHealth in June 2017. Altor Bioscience has raised $92.71 million across 30 funding rounds from investors including NantHealth, HHS and National Cancer Institute. Altor Bioscience offers products and services including ANKTIVA, NK-92 Cell Line, and rBCG. Altor Bioscience operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter United States
- Founders Hing Wong
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immunitybio, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$92.71 M (USD)
in 30 rounds
-
Latest Funding Round
$4.19 M (USD), Grant
Sep 30, 2018
-
Investors
NantHealth
& 3 more
-
Employee Count
Not available
-
Acquired by
NantHealth
(Jun 27, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Altor Bioscience
Altor Bioscience offers a comprehensive portfolio of products and services, including ANKTIVA, NK-92 Cell Line, and rBCG.
Enhances immune system to treat bladder and other cancers.
Provides natural killer cells for bioanalytical testing in trials.
Recombinant BCG for addressing BCG shortages in cancer treatment.
People of Altor Bioscience
Unlock access to complete
Unlock access to complete
Funding Insights of Altor Bioscience
Altor Bioscience has successfully raised a total of $92.71M across 30 strategic funding rounds. The most recent funding activity was a Grant round of $4.19 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Altor Bioscience
Altor Bioscience has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NantHealth, HHS and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biomedical investment financing and active management services.
|
Locked | Locked | Locked | |
|
Cancer research is conducted and supported by the institute.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Altor Bioscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Altor Bioscience
Investment portfolio details for Altor Bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Altor Bioscience
Detailed financials for Altor Bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Altor Bioscience Comparisons
Peer comparison for Altor Bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Altor Bioscience
Altor Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Altor Bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Altor Bioscience
Complete news archive for Altor Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Altor Bioscience
Altor Bioscience was founded in 2002.
Altor Bioscience is headquartered in United States.
Hing Wong is the current CEO of Altor Bioscience. They have also founded this company.
Altor Bioscience is a funded company, having raised a total of $92.71M across 30 funding rounds to date.
Altor Bioscience was founded in 2002 in the United States. Focus is placed on the biotechnology sector, where cell and immunotherapy products are developed for treating cancer and infectious diseases. The product pipeline features Anktiva, targeted at bladder and lung cancer. Operations center on advancing these therapeutic options through research and development efforts.
Altor Bioscience's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Altor Bioscience offers ANKTIVA, NK-92 Cell Line, and rBCG.
Altor Bioscience has 4 investors. Key investors include NantHealth, HHS, National Cancer Institute, and Sanderling Ventures.